Kawakami H, Kadowaki S, Makiyama A, Tsuda M, et al. Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer. J Clin Oncol 2025;43:2184-2195.
PMID: 40378356